<qa>  What is the response rate in HER2 overexpressing metastatic breast cancer?The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer MBC. The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly. 